Psoriasis News and Research

Latest Psoriasis News and Research

Vitamin D: A multi-purpose nutrient for overall health

A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic."

24 Nov 2009

Bio-Quant to be acquired by NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.

23 Nov 2009

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data.

23 Nov 2009

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis.

20 Nov 2009

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

The newly discovered Th22 cells are a previously unknown subset of T helper cells. T helper cells are white blood cells that help activate other immune cells when the body is infected by viruses or bacteria. At the same time they help the body to tolerate own tissue and to prevent or curb inflammation.

20 Nov 2009

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that is due to expire at the end of December.

19 Nov 2009

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Professor John F. Thompson, MD, Professor of Melanoma and Surgical Oncology at the University of Sydney, Director of the Melanoma Institute Australia, and Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany.

17 Nov 2009

Th22 cell to control inflammation in body to help fight off infection discovered

A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time in the Journal of Clinical Investigation.

17 Nov 2009

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

A seminar on Genetic Screening for Psoriatic Arthritis will be presented on Tuesday, December 8 from 12-1 PM Pacific Standard Time, hosted by pharmacogenomics research and development innovators PsoriasisDX, pioneers of the world’s first genetic test for psoriatic arthritis (PsA). The seminar will feature leading experts Dr. John Koo and Dr. Wilson Liao.

17 Nov 2009

PhotoMedex to host free seminar to fight against psoriasis with XTRAC Excimer Lasers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

16 Nov 2009

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Centocor Ortho Biotech's Stelara, the first interleukin (IL)-12/23 inhibitor to enter the psoriasis drug market in the U.S., is expected to change the prescribing habits of dermatologists and substantially alter patient flow to currently marketed biologic agents, including Amgen's Enbrel and Abbott's Humira.

12 Nov 2009

Lerner Medical Devices selects QuantumMethod for branding and launching its Levia phototherapy device

QuantumMethod announced today that Lerner Medical Devices, Inc. has selected the firm as agency of record, tasked with branding and launching Levia®, the company's new Personal Targeted Phototherapy™ device for the self-treatment of psoriasis. Levia® enables their patients to target their small area and scalp psoriasis with therapeutic ultraviolet light via proprietary delivery systems designed for precise, fast and safe treatment.

11 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Alliance Québécoise du Psoriasis provides information concerning H1N1 vaccination campaign

The Alliance Québécoise du Psoriasis (Quebec psoriasis alliance) would like to give its members and other psoriasis sufferers information concerning the massive H1N1 vaccination campaign.

6 Nov 2009

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.

6 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

Nano-size capsule that boosts the body's uptake of curcumin being developed

Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases. Their study is in ACS' Journal of Agricultural and Food Chemistry, a bi-weekly publication.

5 Nov 2009

Foamix' emollient foam platform awarded Mexican patent

Foamix Ltd., a leading developer of topical foams for dermatological and gynecological use, announced today that it has been awarded Mexican Patent Registration No. 268451 entitled "Cosmetic and Pharmaceutical Foam." The patent covers Foamix's vehicles, compositions and cosmetic and pharmaceutical uses thereof based on the company's Emollient Foam technology platform.

4 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Psoriasis News and Research

Latest Psoriasis News and Research

Vitamin D: A multi-purpose nutrient for overall health

Bio-Quant to be acquired by NexMed

Provectus Pharmaceuticals announces Phase 1 interim study data of PV-10 for metastatic melanoma

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

Ligand Pharmaceuticals receives $2 million in milestone payments from N. V. Organon

Melanoma Institute director to present Phase 2 study data of PV-10 for metastatic melanoma

Th22 cell to control inflammation in body to help fight off infection discovered

PsoriasisDX to present seminar on Genetic Screening for Psoriatic Arthritis

PhotoMedex to host free seminar to fight against psoriasis with XTRAC Excimer Lasers

Stelara expected to change dermatologists’ prescribing habits and alter patient flow models

Lerner Medical Devices selects QuantumMethod for branding and launching its Levia phototherapy device

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Alliance Québécoise du Psoriasis provides information concerning H1N1 vaccination campaign

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Bursting common myths about psoriasis

Nano-size capsule that boosts the body's uptake of curcumin being developed

Foamix' emollient foam platform awarded Mexican patent

Safeguard Scientifics reports financial results for the third quarter of 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Innovation in neuroscience drug discovery - eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Psoriasis News and Research

Latest Psoriasis News and Research

Innovation in neuroscience drug discovery - eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in